SCHEMBL1243145

SCHEMBL1243145

CCC(N)(CC)C(CC1CCCCC1)P(=O)(O)O

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.46
ACP3 P15309 2/20 0.36
ANPEP P15144 2/20 0.35
ERAP2 Q6P179 2/20 0.35
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
CA9 Q16790 1/20 0.33
METAP2 P50579 1/20 0.33
FDPS P14324 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL777378 0.76 METAP1 (0.47) METAP1ACP3ANPEPERAP2CA12
SCHEMBL18230965 0.70 FDPS (0.55) METAP1ACP3ANPEPERAP2CA12
SCHEMBL4104306 0.67 METAP1 (0.49) METAP1ACP3ANPEPERAP2CA12
SCHEMBL7435009 0.66 METAP1 (0.51) METAP1ACP3ANPEPERAP2METAP2
SCHEMBL7431441 0.66 METAP1 (0.51) METAP1ACP3ANPEPERAP2METAP2
SCHEMBL7436524 0.65 METAP2 (0.44) METAP1METAP2
SCHEMBL779405 0.65 METAP1 (0.59) METAP1ACP3ANPEPERAP2CA12
SCHEMBL13327340 0.64 FDPS (0.52) METAP1ACP3ANPEPERAP2CA12
SCHEMBL10533248 0.63 CYP1A2 (0.38) METAP1METAP2
SCHEMBL9170443 0.63 METAP1 (0.44) METAP1ACP3ANPEPERAP2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879878-B2 such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation ASTELLAS PHARMA INC. (JP) 2011-02-01 US disclosed